
GSK injects $60 million and 58 jobs into Victoria
6 February 2012
GSK announced that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria...

6 February 2012
GSK announced that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria...

6 February 2012
Company Confirms Plans to File NDA for Suvorexant in 2012...

6 February 2012
The European Commission has approved the use of Galvus® (vildagliptin)...

3 February 2012
Expiration of the HSR waiting period for acquisition of Inhibitex, Inc...

3 February 2012
Research collaboration agreement to develop new insights into the causes of diabetes...

2 February 2012
JANUMET XR can help many patients reach blood sugar goals...

2 February 2012
AstraZeneca has announced new restructuring initiatives designed to improve productivity and strengthen the company’s capabilities...

1 February 2012
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...

30 January 2012
Partners pledge innovative, coordinated action aimed at new WHO goals...

30 January 2012
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...

30 January 2012
Jentadueto™ tablets approved...
This free to view PAT supplement is sponsored by Sartorius, Extrel, ABB, Bruker Optics and FOSS NIRSystems:
ABB Analytical Measurements | Almac | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Daltonik GmbH | CAMO Software AS | CI Precision | Cisbio Bioassays | Colder Products Company | Expo Technologies, LLC. | Freeman Technology | GE Analytical Instruments | HACH LANGE GMBH | HORIBA Scientific | Hudson Robotics, Inc. | Natoli Engineering Company, Inc. | Peter Huber Kältemaschinenbau GmbH | Randox Pharma Services | Rapid Micro Biosystems | Synbiosis | Syngene | Watson-Marlow Pumps Group |
© Russell Publishing Limited, 2010-2012. All rights reserved | Website design and development by e-Motive Media | Terms & conditions of use | Privacy policy
Login to access exclusive content